PDF herunterladen
J Neurol Surg B Skull Base 2017; 78(05): 371-379
DOI: 10.1055/s-0037-1601889
Original Article
Georg Thieme Verlag KG Stuttgart · New York

Comparative Proteomic Profiling Using Two-Dimensional Gel Electrophoresis and Identification via LC-MS/MS Reveals Novel Protein Biomarkers to Identify Aggressive Subtypes of WHO Grade I Meningioma

Joshua W. Osbun
1   Department of Neurological Surgery, University of Washington, Seattle, Washington, United States
,
Philip D. Tatman
1   Department of Neurological Surgery, University of Washington, Seattle, Washington, United States
,
Sumanpreet Kaur
1   Department of Neurological Surgery, University of Washington, Seattle, Washington, United States
,
Carolina Parada
1   Department of Neurological Surgery, University of Washington, Seattle, Washington, United States
,
Tina Busald
1   Department of Neurological Surgery, University of Washington, Seattle, Washington, United States
,
Luis Gonzalez-Cuyar
2   Department of Neuropathology, University of Washington, Seattle, Washington, United States
,
Min Shi
2   Department of Neuropathology, University of Washington, Seattle, Washington, United States
,
Donald E. Born
3   Department of Neuropathology, Stanford University, Stanford, California, United States
,
Jing Zhang
2   Department of Neuropathology, University of Washington, Seattle, Washington, United States
,
Manuel Ferreira
1   Department of Neurological Surgery, University of Washington, Seattle, Washington, United States
› Institutsangaben
Weitere Informationen

Publikationsverlauf

07. November 2015

03. März 2017

Publikationsdatum:
26. April 2017 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Abstract

Background Meningomas represent the most common primary intracranial tumor. The majority are benign World Health Organization (WHO) Grade I lesions, but a subset of these behave in an aggressive manner. Protein biomarkers are needed to distinguish aggressive from benign Grade I lesions.

Materials and Methods Pooled protein lysates were derived from five clinically aggressive Grade I and five typically benign WHO Grade I tumors snap frozen at the time of surgery. Proteins were separated in each group using two-dimensional gel electrophoresis (2DGE) and protein spots of interest were identified using liquid chromatography–mass spectrometry (LC-MS). Potential biomarker candidates were validated using western blot assays in individual tumor samples and by tissue microarray (TMA).

Results Seven candidate biomarkers were obtained from the 2DGE and validated via western blot and TMA. Biomarker validation data allowed for the creation of predictive models using binary logistical regression that correctly identified 85.9% of aggressive tumors within the larger cohort of Grade I meningioma.

Conclusion Simple protein separation by 2DGE and identification of candidate biomarkers by LC-MS allowed for the identification of seven candidate biomarkers that when used in predictive models accurately distinguish aggressive from benign behavior in WHO Grade I meningioma.

Keywords

meningioma - proteomic - two-dimensional gel electrophoresis - mass spectrometry - biomarker discovery

Supplementary Material

 

  • References

  • 1 Cahill KS, Claus EB. Treatment and survival of patients with nonmalignant intracranial meningioma: results from the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute. Clinical article. J Neurosurg 2011; 115 (02) 259-267
    CrossrefPubMedGoogle Scholar
  • 2 Vernooij MW, Ikram MA, Tanghe HL. , et al. Incidental findings on brain MRI in the general population. N Engl J Med 2007; 357 (18) 1821-1828
    CrossrefPubMedGoogle Scholar
  • 3 Nakasu S, Hirano A, Shimura T, Llena JF. Incidental meningiomas in autopsy study. Surg Neurol 1987; 27 (04) 319-322
    CrossrefPubMedGoogle Scholar
  • 4 Louis DN, Ohgaki H, Wiestler OD. , et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114 (02) 97-109
    CrossrefPubMedGoogle Scholar
  • 5 Backer-Grøndahl T, Moen BH, Torp SH. The histopathological spectrum of human meningiomas. Int J Clin Exp Pathol 2012; 5 (03) 231-242
    Google Scholar
  • 6 Gay E, Lages E, Ramus C. , et al. The heterogeneity of meningioma revealed by multiparameter analysis: infiltrative and non-infiltrative clinical phenotypes. Int J Oncol 2011; 38 (05) 1287-1297
    PubMedGoogle Scholar
  • 7 McCarthy BJ, Davis FG, Freels S. , et al. Factors associated with survival in patients with meningioma. J Neurosurg 1998; 88 (05) 831-839
    CrossrefPubMedGoogle Scholar
  • 8 McGovern SL, Aldape KD, Munsell MF, Mahajan A, DeMonte F, Woo SY. A comparison of World Health Organization tumor grades at recurrence in patients with non-skull base and skull base meningiomas. J Neurosurg 2010; 112 (05) 925-933
    CrossrefPubMedGoogle Scholar
  • 9 Nakasu S, Fukami T, Jito J, Nozaki K. Recurrence and regrowth of benign meningiomas. Brain Tumor Pathol 2009; 26 (02) 69-72
    CrossrefPubMedGoogle Scholar
  • 10 Pérez-Magán E, Campos-Martín Y, Mur P. , et al. Genetic alterations associated with progression and recurrence in meningiomas. J Neuropathol Exp Neurol 2012; 71 (10) 882-893
    CrossrefPubMedGoogle Scholar
  • 11 Serna E, Morales JM, Mata M. , et al. Gene expression profiles of metabolic aggressiveness and tumor recurrence in benign meningioma. PLoS One 2013; 8 (06) e67291
    CrossrefPubMedGoogle Scholar
  • 12 Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 1957; 20 (01) 22-39
    CrossrefPubMedGoogle Scholar
  • 13 Cerdá-Nicolás M, López-Gineś C, Pérez-Bacete M, Barcia-Salorio JL, Llombart-Bosch A. Histopathological and cytogenetic findings in benign, atypical and anaplastic human meningiomas: a study of 60 tumors. J Neurooncol 2000; 47 (02) 99-108
    CrossrefPubMedGoogle Scholar
  • 14 Bouamrani A, Ramus C, Gay E. , et al. Increased phosphorylation of vimentin in noninfiltrative meningiomas. PLoS One 2010; 5 (02) e9238
    CrossrefPubMedGoogle Scholar
  • 15 Stuart JE, Lusis EA, Scheck AC. , et al. Identification of gene markers associated with aggressive meningioma by filtering across multiple sets of gene expression arrays. J Neuropathol Exp Neurol 2011; 70 (01) 1-12
    CrossrefPubMedGoogle Scholar
  • 16 Wibom C, Mörén L, Aarhus M. , et al. Proteomic profiles differ between bone invasive and noninvasive benign meningiomas of fibrous and meningothelial subtype. J Neurooncol 2009; 94 (03) 321-331
    CrossrefPubMedGoogle Scholar
  • 17 Tang F, Li W, Chen Y, Wang D, Han J, Liu D. Downregulation of hnRNP K by RNAi inhibits growth of human lung carcinoma cells. Oncol Lett 2014; 7 (04) 1073-1077
    CrossrefPubMedGoogle Scholar
  • 18 Bomsztyk K, Denisenko O, Ostrowski J. hnRNP K: one protein multiple processes. BioEssays 2004; 26 (06) 629-638
    CrossrefPubMedGoogle Scholar
  • 19 Ostrowski J, Bomsztyk K. Nuclear shift of hnRNP K protein in neoplasms and other states of enhanced cell proliferation. Br J Cancer 2003; 89 (08) 1493-1501
    CrossrefPubMedGoogle Scholar
  • 20 Cunningham CC, Stossel TP, Kwiatkowski DJ. Enhanced motility in NIH 3T3 fibroblasts that overexpress gelsolin. Science 1991; 251 (4998): 1233-1236
    CrossrefPubMedGoogle Scholar
  • 21 Thompson CC, Ashcroft FJ, Patel S. , et al. Pancreatic cancer cells overexpress gelsolin family-capping proteins, which contribute to their cell motility. Gut 2007; 56 (01) 95-106
    CrossrefPubMedGoogle Scholar
  • 22 Silacci P, Mazzolai L, Gauci C, Stergiopulos N, Yin HL, Hayoz D. Gelsolin superfamily proteins: key regulators of cellular functions. Cell Mol Life Sci 2004; 61 (19-20): 2614-2623
    CrossrefPubMedGoogle Scholar
  • 23 Camby I, Le Mercier M, Lefranc F, Kiss R. Galectin-1: a small protein with major functions. Glycobiology 2006; 16 (11) 137R-157R
    CrossrefPubMedGoogle Scholar
  • 24 Paz A, Haklai R, Elad-Sfadia G, Ballan E, Kloog Y. Galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation. Oncogene 2001; 20 (51) 7486-7493
    CrossrefPubMedGoogle Scholar
  • 25 Garín MI, Chu CC, Golshayan D, Cernuda-Morollón E, Wait R, Lechler RI. Galectin-1: a key effector of regulation mediated by CD4+CD25+ T cells. Blood 2007; 109 (05) 2058-2065
    CrossrefPubMedGoogle Scholar
  • 26 Yang J, Ramnath N, Moysich KB. , et al. Prognostic significance of MCM2, Ki-67 and gelsolin in non-small cell lung cancer. BMC Cancer 2006; 6: 203
    CrossrefPubMedGoogle Scholar
  • 27 Rubinstein N, Alvarez M, Zwirner NW. , et al. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; a potential mechanism of tumor-immune privilege. Cancer Cell 2004; 5 (03) 241-251
    CrossrefPubMedGoogle Scholar
  • 28 Okamoto H, Li J, Vortmeyer AO. , et al. Comparative proteomic profiles of meningioma subtypes. Cancer Res 2006; 66 (20) 10199-10204
    CrossrefPubMedGoogle Scholar
  • 29 Gao R, Yu Y, Inoue A, Widodo N, Kaul SC, Wadhwa R. Heterogeneous nuclear ribonucleoprotein K (hnRNP-K) promotes tumor metastasis by induction of genes involved in extracellular matrix, cell movement, and angiogenesis. J Biol Chem 2013; 288 (21) 15046-15056
    CrossrefPubMedGoogle Scholar
  • 30 Azuma T, Koths K, Flanagan L, Kwiatkowski D. Gelsolin in complex with phosphatidylinositol 4,5-bisphosphate inhibits caspase-3 and -9 to retard apoptotic progression. J Biol Chem 2000; 275 (06) 3761-3766
    CrossrefPubMedGoogle Scholar
  • 31 Kothakota S, Azuma T, Reinhard C. , et al. Caspase-3-generated fragment of gelsolin: effector of morphological change in apoptosis. Science 1997; 278 (5336): 294-298
    CrossrefPubMedGoogle Scholar
  • 32 Clark VE, Erson-Omay EZ, Serin A. , et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 2013; 339 (6123): 1077-1080
    CrossrefPubMedGoogle Scholar
  • 33 Riobó N, Lu K, Ai X, Haines G, Emerson CP. Phosphoinositide 3-kinase and Akt are essential for sonic hedgehog signaling. Proc Natl Acad Sci U S A 2006; 103 (12) 4505-4510
    CrossrefPubMedGoogle Scholar
  • 34 Ciarlo M, Benelli R, Barbieri O. , et al. Regulation of neuroendocrine differentiation by AKT/hnRNPK/AR/β-catenin signaling in prostate cancer cells. Int J Cancer 2012; 131 (03) 582-590
    CrossrefPubMedGoogle Scholar
  • 35 Olson EN, Nordheim A. Linking actin dynamics and gene transcription to drive cellular motile functions. Nat Rev Mol Cell Biol 2010; 11 (05) 353-365
    CrossrefPubMedGoogle Scholar